| Authors: |
Salem F; DMPK Modelling, DMPK, GSK, Stevenage, UK., Tabatabaeian Nimavardi A; Certara UK Limited, Simcyp Division, 1 Concourse Way, Level 2 Acero, Sheffield, UK., Srivastava A; Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Krollik K; Global Drug Product Development, the healthcare business of Merck KGaA, Darmstadt, Germany., Reichel A; Preclinical Modeling & Simulation, Pharma R&D, Bayer AG, Berlin, Germany., Cebrian D; Integrated Drug Discovery, Selvita SA, Podole 79, 30-394, Kraków, Poland., Taskar KS; DMPK Modelling, DMPK, GSK, Stevenage, UK., Yates JWT; DMPK Modelling, DMPK, GSK, Stevenage, UK., Rynn C; Translational PKPD and Clinical Pharmacology, Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, UK., Duevel HM; NCE DMPK, the healthcare business of Merck KGaA, Darmstadt, Germany. heide.duevel@merckgroup.com. |